Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • Cure & Immunotherapy
      • Brain & Mental Health
      • Therapeutics
      • Tuberculosis
      • Social Behavioral Scientific Core (SBSC)
    • Early Career Investigator Program
    • Staff Spotlights
    • Funding Acknowledgements
    • Network Sites
      • Study Site Map
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
    • Community Meetings and Webinars
  • News & Events
    • Events and Conferences
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
    • Spotlight Series
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • MiLab Resources
      • Specimen Repository
    • Manual of Procedures
    • Media Release Form
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
    • NIH Updates
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Mark Mirochnick

Email

markm@bu.edu

Phone

617-414-3754

Institution

Department of Pediatrics, Boston University School of Medicine

Title

Address

Department of Pediatrics, Boston University School of Medicine
801 Albany Street, Room 2020

Boston, MA 02118
United States of America
Request an Update

Affiliated Studies

P1026S: PK in Pregnancy

DAIDS Number

Therapeutics

Research Area

Treatment

Study Status

Closed to Follow Up

P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

DAIDS Number

11882

Research Area

Therapeutics

Study Status

Closed to Follow Up

IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States.

DAIDS Number

38746

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

P1032: Prevention of Development of Nevirapine-Resistance Mutations in Postpartum Women

DAIDS Number

10137

Research Area

Other

Study Status

Concluded

P1110: Safety and PK of RAL in Neonates

DAIDS Number

11891

Research Area

Treatment

Study Status

Concluded
Show All
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Sitemap Privacy Notice

© 2026 IMPAACT Network